Nucleic acid vaccines

Dengue fever is the most dominant mosquito-borne viral disease, threatening almost half of the world's population in 129 countries, mainly in tropical and subtropical regions. Two vaccines are currently approved, but their use is restricted to a particular category of patients, depending on their age and dengue vaccination status. Therefore, there is still a global need for a vaccine against dengue fever that can be administered to all patients regardless of age and serostatus. This project, developed in collaboration with the team of Dr. Ketloy of Chulalongkorn University (Thailand), aims to meet this need and develop a safe, easily produced and cost-effective tetravalent vaccine against dengue fever. To improve vaccine accessibility, the developed vaccine should also be stable at fridge or room temperature. To achieve this goal, tetravalent nucleic acid lipid-based formulations are being developed and optimized using a Rational Design of Experiments approach.